Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 20/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23358555 | 1.00 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL23358552 | 1.00 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL23358479 | 0.86 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL23358484 | 0.86 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL24907024 | 0.80 | AOC2 (0.67) | AOC2MAOBMAOA | |
| SCHEMBL23358454 | 0.79 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL30006717 | 0.79 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL23358455 | 0.79 | AOC2 (1.00) | AOC2MAOBMAOA | |
| SCHEMBL23329445 | 0.78 | AOC2 (0.64) | AOC2MAOBMAOA | |
| SCHEMBL23358644 | 0.76 | AOC2 (1.00) | AOC2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326721-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-11964942-B2 | SSAO inhibitors and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2024-04-23 | — | — | US | disclosed |
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2023-01-26 | — | — | US | disclosed |
| US-11472769-B2 | SSAO inhibitors and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964942-B2 | SSAO inhibitors and use thereof | SSB, HAO1, SORD | AOC2 39/4885MAOB 21/4885MAOA 17/4885 |
| US-20250326721-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885MAOB 21/4885MAOA 17/4885 |
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885MAOB 21/4885MAOA 17/4885 |
| US-11472769-B2 | SSAO inhibitors and use thereof | SSB, HAO1, SORD | AOC2 39/4885MAOB 21/4885MAOA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.